MoonLake Immunotherapeutics (MLTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MLTX? Forum Prognose

Warum fällt MoonLake Immunotherapeutics-Aktie (MLTX)?

Wir haben während der Handelssitzung 2024-05-10 einen Rückgang der Aktie MoonLake Immunotherapeutics (MLTX) um 5.00% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!

2023-11-06:

Moonlake Immunotherapeutics Stock (MLTX) dropped by 29.11% from $51.28 to $36.35 in the trading on Monday November 6, 2023. The reason why MLTX stock down today is due to the topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with active psoriatic arthritis (PsA). The company said that the 207-patient trial met its primary endpoint with a statistically significant effect while the 60mg dose without induction did not reach statistical significance for the primary endpoint. Although the trial was positive, it was difficult to reach conclusions without seeing placebo response rates and analyzing additional details.

2023-09-01:

MoonLake Immunotherapeutics (MLTX) stock was down 6.32% after it filed a shelf registration statement for the potential sale of up to $1 billion of its securities from time to time.

https://twitter.com/AInvestOfficial/status/1697724526652477747